NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine

All requested labeling changes were classified as minor, while the proposed product name remains under FDA review.

Rhea-AI Summary

NRx Pharmaceuticals (NRXP) received an FDA labeling review letter requesting minor changes to its preservative-free ketamine product’s submitted label.

All requested changes were classified as “MINOR.” The FDA requested sample labeling using the proposed proprietary product name, which remains under review, ahead of the November 10, 2026 goal date for the abbreviated new drug application. This application is the generic-drug approval pathway.

NRx is completing final manufacturing process validation runs, which verify the manufacturing process, to comply with product launch requirements. Separately, NRx has initiated a new drug application filing for NRX-100, its preservative-free intravenous ketamine, for suicidal ideation in patients with depression, including bipolar depression.

Positive

• Minor pointFDA labeling review classified all requested changes as “MINOR”.
• Minor pointFinal manufacturing process validation runs are underway to meet product launch requirements.

Negative

• Minor pointFDA requested revised sample labeling ahead of the November 10, 2026 application goal date.
• Minor pointProposed proprietary product name remains under FDA review.

Key Figures

GDUFA goal date: November 10, 2026

GDUFA goal date

November 10, 2026

ANDA review

Historical Context

1 past event · Latest: Sep 15

1 event

1. Sep 15

   FDA amendment reclassification

   24h Move

   -2.6%

   FDA reclassified the ANDA amendment as minor and set a November 10 GDUFA goal date.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gdufa, abbreviated new drug application, process validation, fast track designation, +1 more

5 terms

gdufa regulatory

"November 10, 2026, GDUFA goal date"

GDUFA is a U.S. regulatory program that charges fees to makers of generic drugs to fund and speed up the government review and inspection process for generic medicines and manufacturing sites. For investors, it matters because the program influences how fast generics reach the market, the cost burden on manufacturers, and the ability of companies to scale production—similar to paying for faster processing at a government office that can affect a business’s timing and margins.

abbreviated new drug application regulatory

"Abbreviated New Drug Application GDUFA goal date"

An abbreviated new drug application is a regulatory submission used to gain approval to market a generic version of an already approved prescription medicine by showing it is equivalent in effect and safety to the original product, without repeating full clinical trials. For investors, an approval signals a lower-cost competitor entering the market that can quickly capture sales from the branded drug, similar to a generic knock‑off replacing a name‑brand item on store shelves.

process validation technical

"completing final manufacturing Process Validation Runs"

Process validation is the documented proof that a manufacturing or production method reliably and consistently makes a product that meets required quality and safety standards. Think of it like proving a recipe always produces the same good cake: once validated, the process reduces the chance of defects, regulatory problems, production delays and costly recalls, so investors view it as a sign of lower operational and compliance risk.

fast track designation regulatory

"NRX-100 has been awarded Fast Track Designation"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

breakthrough therapy designation regulatory

"NRX-101 has been awarded Breakthrough Therapy Designation"

A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• In advance of November 10, 2026, GDUFA goal date, all requested changes were classified as “MINOR.”
• NRx was requested to prepare and submit labels with the proprietary name currently under review by FDA.
• NRx is currently completing final manufacturing Process Validation Runs to comply with product launch requirements.
  
  

WILMINGTON, Del., Oct. 15, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the receipt of a “DISCIPLINE REVIEW LETTER” from the US Food and Drug Administration requesting “MINOR” changes to the submitted label for NRx’s Preservative-Free Ketamine product. The letter requests that the Company submits sample labeling with the proposed proprietary product name currently under review in advance of the November 10, 2026, Abbreviated New Drug Application GDUFA goal date.

“We at NRx deeply appreciate the engagement of the FDA Office of Generic Drugs and their focus on completing review of our product by the GDUFA goal date,” said Jonathan Javitt, MD, MPH, the Company’s Chairman and CEO. “The supply of ketamine in the United States has been primarily from overseas manufacture and American hospitals and doctors have been plagued by repeated shortages of this critically important drug. We look forward to demonstrating that manufacture of drugs such as this can successfully be re-shored to the United States. We believe that making a preservative-free preparation of ketamine is important for patients and appreciate the willingness of FDA to work with us on an appropriate product name.”

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the FDA request for NRx Pharmaceuticals’ preservative-free ketamine labeling?

The FDA requested minor label changes and sample labeling using the proposed proprietary product name. All requested changes were classified as “MINOR,” and the proposed name remains under FDA review.

What is the FDA review goal date for NRx Pharmaceuticals’ preservative-free ketamine application?

The abbreviated new drug application has a November 10, 2026 GDUFA goal date. The FDA requested sample labeling with the proposed proprietary product name ahead of that date.